MIGDAL HA'EMEQ, Israel, Sept. 28, 2013 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY) today announced that the underwriters of its initial public offering had exercised in full their option to purchase an additional 661,800 ordinary shares from the Company at the initial public offering price. The offering is expected to close on October 2, 2013, subject to customary closing conditions. As a result of the exercise of the option, a total of 5,073,800 shares are being offered by the Company raising gross offering proceeds of $71.0 million and net proceeds from the offering to the Company of approximately $63.5 million, after deducting the underwriting discount and estimated offering expenses. The Company intends to use the net proceeds from the offering to meet its anticipated increased working capital requirements resulting from the expected growth in the Company's business and for other general corporate purposes. BofA Merrill Lynch and Jefferies LLC acted as joint book-running managers for the offering. Wells Fargo Securities, LLC acted as lead manager for the offering. Canaccord Genuity and Wedbush Securities acted as co-managers for the offering. This offering is being made solely by means of a prospectus, copies of which may be obtained from either: BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attention: Prospectus Department or emailing firstname.lastname@example.org; or Jefferies LLC, 520 Madison Ave, 12th Floor, New York, NY 10022, 877-547-6340, email: Prospectus_Department@Jefferies.com. A registration statement relating to these securities has been filed with and declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Enzymotec Ltd.Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-functional lipid ingredients, as well as final products, based on sophisticated processes and technologies.
CONTACT: ICR Katie Turner 646-277-1228 Katie.Turner@icrinc.com John Mills 310-954-1105 John.Mills@icrinc.com